Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 ...

CNBC's Jim Cramer said Moderna's expanding pipeline in treatments for cancer and other diseases provides a compelling ...

The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas.

Pembrolizumab is used to treat various types of cancer, including melanoma, non-small cell lung cancer and head and neck squamous cell cancer.

AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...

Sen. Maggie Hassan is pressing pharmaceutical giant Merck over access and cost issues around one of its most popular and best ...

Merck (NYSE: MRK) closed Tuesday's session down 0.87% at $128.26, breaking a six-session winning streak. The stock had gained 13.62% over the preceding six trading sessions, outperforming the S&P 500, ...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended the use of Keytruda (pembrolizumab), within ...

US FDA approves Keytruda and Keytruda Qlex, each with Trodelvy as first-line treatment of PD-L1+ (CPS =10) advanced TNBC: Rahway, New Jersey Friday, June 26, 2026, 09:00 Hrs [IST] ...

Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...